$60M B round to propel Landos through Phase II IBD trials

Landos' $60 million series B will enable it to complete two Phase II trials, one each in ulcerative colitis and Crohn's disease, of lead product BT-11.

Chairman, President and CEO Josep Bassaganya-Riera told BioCentury he expects the funding to last Landos Biopharma Inc. (Blacksburg, Va.) until 2021 and that the bulk of it will go toward the Phase II inflammatory bowel disease trials of the first-in-class oral LANCL2 agonist...